Fecal glycoprotein 2 is a marker of gut microbiota dysbiosis and systemic inflammation.

Authors

Fabian Frost, Stefan Weiss, Johannes Hertel, Malte Rühlemann, Corinna Bang, Andre Franke, Matthias Nauck, Marcus Dörr, Henry Völzke, Dirk Roggenbuck, Peter Schierack, Uwe Völker, Georg Homuth, Ali A Aghdassi, Matthias Sendler, Markus M Lerch, Frank U Weiss

Year of publication

2024

Journal

GUT PATHOG

Volume

16

Issue

1

ISSN

1757-4749

Impact factor

3.274

Abstract

Background

Antimicrobial autoantigenic glycoprotein 2 (GP2) is an important component of the innate immune system which originates from the exocrine pancreas as well as from the small intestines. The relationship of GP2 with the intestinal microbiome as well as the systemic implications of increased fecal GP2 levels are, however, still unclear. Therefore, fecal samples from 2,812 individuals of the Study of Health in Pomerania (SHIP) were collected to determine GP2 levels (enzyme-linked immunosorbent assay) and gut microbiota profiles (16 S rRNA gene sequencing). These data were correlated and associated with highly standardised and comprehensive phenotypic data of the study participants.

Results

Fecal GP2 levels were increased in individuals with higher body mass index and smokers, whereas lower levels were found in case of preserved exocrine pancreatic function, female sex or a healthier diet. Moreover, higher GP2 levels were associated with increased serum levels of high-sensitivity C-reactive protein, loss of gut microbial diversity and an increase of potentially detrimental bacteria (Streptococcus, Haemophilus, Clostridium XIVa, or Collinsella). At the same time, predicted microbial pathways for the biosynthesis of beneficial short-chain fatty acids or lactic acid were depleted in individuals with high fecal GP2. Of note, GP2 exhibited a stronger association to overall microbiome variation than calprotectin.

Conclusion

Fecal GP2 is a biomarker of gut microbiota dysbiosis and associated with increased systemic inflammation. The intestines may be more important as origin for GP2 than pancreatic acinar cells. Future studies need to investigate the potential clinical value in disease specific patient cohorts.